XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan [clinicaltrials:NCT01086228]

Bio2RDF identifier

NCT01086228

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01086228

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01086228

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

2,032

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01086228 arm group cba574f3dd3842a8af68ac883acc1a9b [clinicaltrials_resource:NCT01086228/arm-group/cba574f3dd3842a8af68ac883acc1a9b]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:9fe0fc90d23f5bfbdb377da0b1c5d7b0

brief summary [clinicaltrials_vocabulary:brief-summary]

The objectives of this ...... n of the efficacy and safety.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

XIENCE V/PROMUS Everolimus-Elu ...... urveillance Protocol for Japan

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:8c38cbb24b2708e8a40e7eb128d8af7c]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:d00c19478c8d870b6ebfffe3668ab20d]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:178449c40b3915552a459fd891d6f6cf]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:1813a41b56a75ef8fd5f6448539a9b68]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:2e0c56ddca1e1921f175236c3235bd92]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:34e03a9c45e94a66ef56c60759599de2]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:3d379abddd6a9a949e8068771dad6e8a]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:41f47c566cc0e8f32e1c4ebb4740c442]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:6ffb095022cafe2ee611cf44b2b35b96]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:758e931e9aa9cb09d16db8ec2942ff35]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:91160c352471fd4f166f0e58ef0d275f]

(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition. 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure [clinicaltrials_resource:a00ec99f418df189ec7d0bb946311b06]

completion date [clinicaltrials_vocabulary:completion-date]

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

The surveillance is to ...... and Tests of Medical Devices.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01086228 [clinicaltrials_resource:368518953428faf29b1d09ab409fcd02]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

XIENCE V / PROMUS stent [clinicaltrials_resource:a3d81f9b180df0f3c088af775ae37456]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Angioplasty

http://www.w3.org/2001/XMLSchema#string

Drug eluting stents

http://www.w3.org/2001/XMLSchema#string

Stents

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Abbott Vascular [clinicaltrials_resource:8e3a5abde04275155f38f1e3c8c608e6]

location [clinicaltrials_vocabulary:location]

Site Reference ID/Investigator# 104727 [clinicaltrials_resource:b255de677126e1e54aa95d17fbf35a65]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01086228

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

XIENCE V/PROMUS Everolimus-Elu ...... arketing Surveillance Protocol

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

09-384

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Gary Thompson [clinicaltrials_resource:a6ef4d7ed8e466f75050e71b41ecc036]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

Japan: Pharmaceuticals and Medical Devices Agency [clinicaltrials_resource:3466094b9b4632620642ee3720974c38]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Abbott Vascular [clinicaltrials_resource:8e3a5abde04275155f38f1e3c8c608e6]

start date [clinicaltrials_vocabulary:start-date]

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01086228 study design [clinicaltrials_resource:deb4db3b64cdb7288c067acb4f7ba602]

study type [clinicaltrials_vocabulary:study-type]

Observational [clinicaltrials_resource:d91f8943e6c920253e1301b3d81445a1]

url [clinicaltrials_vocabulary:url]

NCT01086228

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01086228

http://www.w3.org/2001/XMLSchema#string

title

XIENCE V/PROMUS Everolimus-Elu ...... urveillance Protocol for Japan

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

XIENCE V/PROMUS Everolimus-Elu ...... n [clinicaltrials:NCT01086228]

@en